NCT03402399

Unknown

Defining the Molecular Risk in Israeli Patients With Seconda...

Assaf-Harofeh Medical Center Source

Compare

Other study identifiers

Sponsor study identifier

0124-17

Study Type

interventional

Estimated enrollment

222

Locations

1 country

Sites

1

Timeline

Study Start

December 10, 2017

Actual (reported)

Primary Completion

December 9, 2019

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

December 9, 2020

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Brief Summary

The aim of the study is to determine the rate of HMR mutations in PMF and secondary MF (post PV/ET) subjects, and correlate the rate of mutations with clinical features as known prognostic scores.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Estimated enrollment: 222 participants
Study completion date: December 9, 2020
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
December 10, 2017
Actual (reported)
First Submitted
January 11, 2018
Actual (reported)
First Posted
January 18, 2018
Actual (reported)
Primary Completion
December 9, 2019
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 9, 2020
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated: July 5, 2019
Status Verified: July 2019
Last Update Submitted: July 2, 2019

Conditions

Myelofibrosis, Post ET Myelofibrosis, Post PV Myelofibrosis, Primary

Outcome Measures

Primary Outcomes (1)

Rate of patients with one or more HMR mutations in primary compared to secondary (post PV/ET) MF
Proportions of patients with HMR mutations in each arm
Baseline

Study Arms (2)

Primary Myelofibrosis

OTHER

Blood test

Other: Molecular analysis

Secondary Myelofibrosis

OTHER

Blood test

Other: Molecular analysis

Interventions

Molecular analysisOther

Blood test

Primary MyelofibrosisSecondary Myelofibrosis

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Diagnosis of PMF, post PV MF or post ET MF according to the WHO 2008 classification
Age . 18 years

Sponsors & Collaborators

Assaf-Harofeh Medical Center
Governmentlead

Study Sites (1)

Assaf Harofeh Medical Center

Ẕerifin, Israel

RECRUITING

Maya Koren-Michowitz, MDCONTACTkorenm@asaf.health.gov.il

MeSH Terms

Conditions

Primary Myelofibrosis

Condition Hierarchy (Ancestors)

Myeloproliferative DisordersBone Marrow DiseasesHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

Maya Koren-Michowitz, MD
Assaf-Harofeh Medical Center
PRINCIPAL INVESTIGATOR

Central Study Contacts

Shirly Broitman

CONTACT

+972-8-9778452 shirlib@asaf.health.gov.il

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: OTHER
Intervention Model: PARALLEL
Sponsor Type: OTHER GOV
Responsible Party: SPONSOR

Study Record Dates

First Submitted

January 11, 2018

First Posted

January 18, 2018

Study Start

December 10, 2017

Actual (reported)

Primary Completion

December 9, 2019

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

NCT05710211

Clonal Architecture of ASXL1-mutated Myelofibrosis

Not ApplicableRecruiting

NCT02469974

Ruxolitinib in Combination With Autotransplant

Not ApplicableWithdrawn

NCT00882752

Report of a New Method Used to Identify the Bacteria Present in a Human Colon Biopsy Sample

Completed

NCT03907436

The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase

Not ApplicableCompleted

NCT06781099

Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis

Not ApplicableRecruiting

NCT02435550

iCare for Cancer Patients

Not ApplicableTerminated

Patient is willing and capable of giving a written informed consent.

Concurrent participation in clinical trials will be allowed

You may not qualify if:

Unwilling or unable to provide informed consent
Prefibrotic MF

Contact the study team to confirm eligibility.

Study Completion

December 9, 2020

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated

July 5, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT03402399
Data provider: ClinicalTrials.gov
Source updated: 2019-07-05
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:34:49 UTC

Locations

IL(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Primary Myelofibrosis

Secondary Myelofibrosis

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations